PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cutting Edge Information (CEI)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch - Market access priorities shift from market research to health economics research during the launch process, finds Cutting Edge Information - CuttingEdgeInfo.com
Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch

 

NewswireToday - /newswire/ - Durham, NC, United States, 2013/06/20 - Market access priorities shift from market research to health economics research during the launch process, finds Cutting Edge Information - CuttingEdgeInfo.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Pharmaceutical companies focus their attention on market research in Phase 3a to market approval, and on health economics and outcomes research (HEOR) from launch to six months post-launch, according to a study published by Cutting Edge Information.

Market access is instrumental in informing future brand strategies. The study,“Launching Pharmaceutical Brands: Formulas for Commercialization Success,” found that between market approval and launch, market research and HEOR resources even out, receiving 11% and 10% of the average budget, respectively. Market access categories’ financial support lessens from launch to six months post-launch. During that timeframe, HEOR becomes the market access priority with 9% of the average total budget while market research receives only 6%.

“Time and again, interviewed executives emphasized the importance of understanding the markets when aiming to achieve a quick sales uptake,” said David Richardson, research manager at Cutting Edge Information. “However, once they achieve this understanding, pharmaceutical companies are free to focus on other important market access categories.”

Surveyed brands focused on market access throughout the commercialization and launch process, though specific attentions changed from Phase 3a to post-launch. Pharmaceutical companies must support many different commercialization efforts to ensure a brand’s successful launch.

During the early stages of commercialization Phase 3a to market approval surveyed companies allocate an average of 17% of their budget to market research. This category is the highest financial priority among market access concerns. At the same time, HEOR receives only 6% of the average budget, less than both market research and pricing and reimbursement concerns.

Cutting Ede Information’s study,“Launching Pharmaceutical Brands: Formulas for Commercialization Success," explores 15 individual pharmaceutical brands’ launches in the US, Canada, Europe and Asia. Use this report to:
• Plan budgets and win necessary resources for commercialization and launch
• Know when and how much to invest in specific areas of advertising and promotion, market access, decision support and medical affairs
• Use benchmarking data to identify investment levels and patterns among comparable brands

For the latest research on global pharmaceutical marketing and brand launch strategy, contact Cassie Demeter at +1 919-403-6583.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cutting Edge Information (CEI)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Cassie Demeter - CuttingEdgeInfo.com 
919-403-6583 cassie_demeter[.]cuttingedgeinfo.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cutting Edge Information (CEI) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cutting Edge Information (CEI) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  1Click Games

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)